CIP2A and cancer: In contrast to the observed survival, the weighted average of expected 5 year survival rate was higher for CIP2A high/KRAS mutant than for CIP2A low/KRAS mutant patient group (Supplementary Table 11), suggesting that high CIP2A expression is an indicator of poor prognosis in KRAS mutant cancers.